Combination L-Glutamine with Gemcitabine and Nab-Paclitaxel in Treatment-Naïve Advanced Pancreatic Cancer: The Phase I GlutaPanc Study Protocol

Advanced pancreatic cancer is underscored by progressive therapeutic resistance and a dismal 5-year survival rate of 3%. Preclinical data demonstrated glutamine supplementation, not deprivation, elicited antitumor effects against pancreatic ductal adenocarcinoma (PDAC) alone and in combination with...

Descripción completa

Detalles Bibliográficos
Autores principales: Gong, Jun, Osipov, Arsen, Lorber, Jeremy, Tighiouart, Mourad, Kwan, Albert K., Muranaka, Hayato, Akinsola, Rasaq, Billet, Sandrine, Levi, Abrahm, Abbas, Anser, Davelaar, John, Bhowmick, Neil, Hendifar, Andrew E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216251/
https://www.ncbi.nlm.nih.gov/pubmed/37239063
http://dx.doi.org/10.3390/biomedicines11051392

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216251/
https://www.ncbi.nlm.nih.gov/pubmed/37239063
http://dx.doi.org/10.3390/biomedicines11051392

Ejemplares similares